HK1033324A1 - Glucagon-like peptide-2 analogs - Google Patents

Glucagon-like peptide-2 analogs

Info

Publication number
HK1033324A1
HK1033324A1 HK00105089A HK00105089A HK1033324A1 HK 1033324 A1 HK1033324 A1 HK 1033324A1 HK 00105089 A HK00105089 A HK 00105089A HK 00105089 A HK00105089 A HK 00105089A HK 1033324 A1 HK1033324 A1 HK 1033324A1
Authority
HK
Hong Kong
Prior art keywords
glucagon
analogs
peptide
synthesis
identified
Prior art date
Application number
HK00105089A
Other languages
English (en)
Inventor
Daniel J Drucker
Anna E Crivici
Martin Sumner-Smith
Original Assignee
Ontario Inc 1149336
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1033324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ontario Inc 1149336, Allelix Biopharma filed Critical Ontario Inc 1149336
Publication of HK1033324A1 publication Critical patent/HK1033324A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK00105089A 1996-04-12 2000-08-15 Glucagon-like peptide-2 analogs HK1033324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12
PCT/CA1997/000252 WO1997039031A1 (fr) 1996-04-12 1997-04-11 Analogues de peptide 2 du type glucagon

Publications (1)

Publication Number Publication Date
HK1033324A1 true HK1033324A1 (en) 2001-08-24

Family

ID=24530501

Family Applications (3)

Application Number Title Priority Date Filing Date
HK00105089A HK1033324A1 (en) 1996-04-12 2000-08-15 Glucagon-like peptide-2 analogs
HK03100905.1A HK1050204B (zh) 1996-04-12 2003-02-07 類升糖素肽-2分子
HK11101311.7A HK1147761A1 (en) 1996-04-12 2003-02-07 Glucagon-like peptide-2 analogs

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK03100905.1A HK1050204B (zh) 1996-04-12 2003-02-07 類升糖素肽-2分子
HK11101311.7A HK1147761A1 (en) 1996-04-12 2003-02-07 Glucagon-like peptide-2 analogs

Country Status (16)

Country Link
EP (5) EP2009024A1 (fr)
JP (3) JP4148994B2 (fr)
CN (1) CN1268640C (fr)
AT (2) ATE478892T1 (fr)
AU (1) AU733857B2 (fr)
BR (1) BRPI9708566B8 (fr)
CA (1) CA2251576C (fr)
DE (2) DE69716905T2 (fr)
DK (2) DK1231219T3 (fr)
ES (2) ES2351661T3 (fr)
FR (1) FR13C0013I2 (fr)
HK (3) HK1033324A1 (fr)
LU (1) LU92153I2 (fr)
NZ (1) NZ332281A (fr)
PT (2) PT906338E (fr)
WO (1) WO1997039031A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CA2251576C (fr) 1996-04-12 2012-08-21 1149336 Ontario Inc. Analogues de peptide 2 du type glucagon
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (fr) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methodes pour ameliorer le fonctionnement du gros intestin
MXPA99010523A (es) * 1997-05-16 2004-09-01 Ontario Inc 1149336 Metodos para mejorar el funcionamiento del tractogastrointestinal superior.
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999058144A1 (fr) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Procedes d'amelioration du fonctionnement du gros intestin
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
EP1592471B1 (fr) * 2003-02-04 2011-03-23 Novo Nordisk A/S Dispositif d'injection comportant un mecanisme de dosage rotatif
PL1664109T3 (pl) * 2003-08-21 2010-01-29 Novo Nordisk As Oczyszczanie peptydów glukagonopodobnych
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
EP1809318B1 (fr) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite
KR101200227B1 (ko) 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
JP5819586B2 (ja) * 2006-11-08 2015-11-24 ジーランド ファーマ アクティーゼルスカブ 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
CN102942626B (zh) * 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (fr) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 en utilisation pour la récupération intestinale et musculaire
EP2314616A1 (fr) * 2009-10-23 2011-04-27 Ferring B.V. Agonistes peptidiques de GLP-2
EP2495255A4 (fr) * 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd Forme glycosylée d'analogue du glp-1 antigénique
CA2797033C (fr) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Polypeptides tres actifs et procedes pour les preparer et les utiliser
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
US20140249090A1 (en) 2011-04-01 2014-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
EP2968469A4 (fr) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptides comprenant des acides aminés non endogènes et procédés de fabrication et d'utilisation associés
WO2018069442A1 (fr) 2016-10-12 2018-04-19 University Of Copenhagen Agonistes doubles peptidiques de gipr et glp2r
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (fr) 2018-07-23 2020-01-30 Zealand Pharma A/S Utilisations thérapeutiques d'agonistes de glp-2
EP3628683A1 (fr) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues de peptide-2 de type glucagon (glp-2)
EP3628682A1 (fr) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues glucagon-like-peptide-2 (glp-2)
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
WO2021198195A1 (fr) 2020-03-30 2021-10-07 Zealand Pharma A/S Combinaison d'agonistes
WO2023111273A1 (fr) * 2021-12-17 2023-06-22 Bainan Biotech Aps Agonistes doubles peptidiques de gipr et glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
CA2137206A1 (fr) 1993-12-09 1995-06-10 John A. Galloway Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK1975177T3 (da) 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
CA2251576C (fr) * 1996-04-12 2012-08-21 1149336 Ontario Inc. Analogues de peptide 2 du type glucagon
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (fr) 2001-02-01 2002-08-29 Drucker Daniel J Renforcement de l'activite de glp-2

Also Published As

Publication number Publication date
BRPI9708566B8 (pt) 2022-01-18
JP2000511881A (ja) 2000-09-12
EP0906338B1 (fr) 2002-11-06
DE69716905D1 (de) 2002-12-12
EP1231219B1 (fr) 2010-08-25
EP2218734A3 (fr) 2010-10-13
CN1244872A (zh) 2000-02-16
EP1231219A1 (fr) 2002-08-14
JP2007204491A (ja) 2007-08-16
ATE478892T1 (de) 2010-09-15
FR13C0013I1 (fr) 2013-05-04
EP0906338A1 (fr) 1999-04-07
DK1231219T3 (da) 2010-12-20
CA2251576A1 (fr) 1997-10-23
EP2275438A1 (fr) 2011-01-19
EP2218734B1 (fr) 2013-06-05
ES2188929T3 (es) 2003-07-01
NZ332281A (en) 2000-03-27
CA2251576C (fr) 2012-08-21
WO1997039031A1 (fr) 1997-10-23
HK1050204A1 (en) 2003-06-13
FR13C0013I2 (fr) 2013-08-16
HK1147761A1 (en) 2011-08-19
DE69716905T2 (de) 2003-07-24
ES2351661T3 (es) 2011-02-09
CN1268640C (zh) 2006-08-09
JP4148994B2 (ja) 2008-09-10
PT1231219E (pt) 2010-11-30
BRPI9708566A (pt) 2000-01-04
JP4149497B2 (ja) 2008-09-10
EP2218734A2 (fr) 2010-08-18
JP5019466B2 (ja) 2012-09-05
JP2008184465A (ja) 2008-08-14
LU92153I2 (fr) 2013-04-19
EP2009024A1 (fr) 2008-12-31
AU2500297A (en) 1997-11-07
DK0906338T3 (da) 2003-03-03
BR9708566B1 (pt) 2012-09-04
HK1050204B (zh) 2011-09-23
AU733857B2 (en) 2001-05-31
ATE227309T1 (de) 2002-11-15
PT906338E (pt) 2003-03-31
DE60142885D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
FR13C0013I1 (fr)
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
AU7917094A (en) Preparation of 3,4,4-trisubstituted-piperidinyl-N- alkylcarboxylates and intermediates
GR3024420T3 (en) Process for the preparation of oxetanones
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
HU902288D0 (en) Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
MX9803672A (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
EP0543023A4 (en) Process for producing astaxanthin by fermentation
DE19680202D2 (de) Arzneistoffe zur selektiven Bekämpfung von Tumorgewebe
HUP9901600A3 (en) Vitamin d analogues, their use, pharmaceutical compositions containing them, process for their production and process producing intermediates
EP0034647A3 (en) 4-aryloxy- and 4-arylthio-3-phenylpiperidine derivatives, a process for the preparation of such compounds and their use as medicaments
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
MX9602804A (es) Derivados del 3-aril-alquenil-1,2,4-oxadiazol y su uso como parasiticidas para animales.
NZ332245A (en) Substituted benzo-oxazolol carboxylic acid derivatives, process for their production and medicaments containing them
GB9100381D0 (en) Human bfgf derivatives,their analogs and process for their production
HU910463D0 (en) Process for the production of medical preparation
HUP9600476A3 (en) Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them
ES2027507A6 (es) Procedimiento de preparacion de derivados selenofenicos.
AU619888C (en) Alpha, alpha - disubstituted n-cycloalkylalkylbenzylamines, process for their preparation, their use as a medicament and their synthesis intermediates
AU634635C (en) 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3- propanediols and related compounds, a process and intermediates for their preparation and their use as medicaments
HU903473D0 (en) Process for the production of beta-cyclodextrine based inclusion as a medical product
MN426A8 (en) Preparation of lactic-acidic product vitaminized by b12 using propion-acidic p.shermani bacteria

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20170410